Citigroup upgraded biopharmaceutical company Adolor (ADLR Quote) to hold from sell, citing a decision from the company's partner GlaxoSmithKline (GSK Quote) to continue with a late-stage program for its bowel treatment drug, Entereg. The firm also upped Adolor's stock price target to $10 from $5. Shares were recently adding 41 cents, or 4.8%, to $9.01.
Nabi Biopharmaceuticals (NABI Quote) was higher after the company posted a narrower-than-expected fourth-quarter loss late Monday. The company also announced plans to cut its operations into two business units, Nabi Biologics and Nabi Pharmaceuticals. The stock was rising 22 cents, or 4.6%, at $5.05. On the other hand, Emisphere Technologies (EMIS Quote) tumbled 10.3% after the company attached an addendum to its fourth-quarter and year-end results. The addendum included a note from Emisphere's accountant that raised doubts that the company had the capital resources and ability to operate after September. Emisphere was off 47 cents to $4.10. Merck (MRK Quote) inched lower after a jury in New Jersey awarded $20 million in compensatory damages and $27.5 million in punitive damages to plaintiffs against the company in a Vioxx-related personal injury case. Merck was recently down 4 cents, or 0.1%, to $44.25. Elsewhere, PDL BioPharma (PDLI Quote) was gaining 1.6% at $19.43. Amgen (AMGN Quote) was higher by 1.4% at $61.54. King Pharmaceuticals (KG Quote) was adding 1% at $18.83. Among losers, Teva Pharmaceutical (TEVA Quote) was off 1.5% at $36.06. Forest Labs (FRX Quote) was recently losing 0.9% at $51.65. Schering-Plough (SGP Quote) was lower by 0.2% at $23.91.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.17
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |














